Last reviewed 2026-04-23 · How we verify

abacavir/lamivudine + darunavir/ritonavir

abacavir/lamivudine + darunavir/ritonavir is a NRTI + PI Small molecule drug developed by University of Modena and Reggio Emilia. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1. Also known as: Kivexa, Prezista, Norvir.

Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while darunavir/ritonavir is a protease inhibitor that blocks the protease enzyme, preventing the maturation of viral particles.

Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while darunavir/ritonavir is a protease inhibitor that blocks the protease enzyme, preventing the maturation of viral particles. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1.

At a glance

Mechanism of action

Abacavir/lamivudine works by incorporating itself into the viral DNA, causing chain termination, while darunavir/ritonavir blocks the protease enzyme, preventing the maturation of viral particles. This combination therapy is used to treat HIV-1 infection. The use of ritonavir as a pharmacokinetic enhancer allows for a lower dose of darunavir to be used, reducing the risk of side effects.

Approved indications

• Treatment of HIV-1 infection in adults and children
• Prevention of mother-to-child transmission of HIV-1

Common side effects

• Nausea
• Diarrhea
• Fatigue
• Headache
• Abdominal pain
• Dizziness
• Insomnia
• Rash
• Vomiting

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
• Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (PHASE3)
• Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
• Dual Therapy With Boosted Darunavir + Dolutegravir (PHASE3)
• Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
• Evaluation of Third-line cART Regimen in Cambodia (3DICAM) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• abacavir/lamivudine + darunavir/ritonavir CI brief — competitive landscape report
• abacavir/lamivudine + darunavir/ritonavir updates RSS · CI watch RSS
• University of Modena and Reggio Emilia portfolio CI

Frequently asked questions about abacavir/lamivudine + darunavir/ritonavir

Related

• Drug class: All NRTI + PI drugs
• Target: All drugs targeting HIV-1 reverse transcriptase, HIV-1 protease
• Manufacturer: University of Modena and Reggio Emilia — full pipeline
• Therapeutic area: All drugs in Infectious Diseases
• Indication: Drugs for Treatment of HIV-1 infection in adults and children
• Indication: Drugs for Prevention of mother-to-child transmission of HIV-1
• Also known as: Kivexa, Prezista, Norvir